Vironova BioAnalytics

Vironova BioAnalytics

Offers a range of products and services which can be used in development of particles for vaccines, drug delivery and gene therapy as well as viral safety testing and material quality control. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2017201820192020202120222023
Revenues4.3m7.3m6.2m9.6m10.8m12.2m12.2m
% growth24 %70 %(14 %)54 %13 %12 %-
EBITDA(4.8m)(4.2m)(7.5m)(7.0m)(16.6m)--
% EBITDA margin(112 %)(58 %)(119 %)(73 %)(154 %)--
Profit(5.7m)(6.0m)(10.3m)(10.8m)(20.3m)--
% profit margin(134 %)(83 %)(164 %)(113 %)(187 %)--

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Grant

€290k

Grant
*

N/A

Acquisition
Total FundingAUD493k

Recent News about Vironova BioAnalytics

Edit
More about Vironova BioAnalyticsinfo icon
Edit

Vironova AB is a biotechnology company specializing in the analysis of nanoparticles using Transmission Electron Microscopy (TEM). The company offers a comprehensive suite of hardware, software, and services designed to provide detailed and accurate nanoparticle analysis. Vironova serves clients in the pharmaceutical and biotechnology industries, helping them to ensure the quality and efficacy of their nanoparticle-based products. Operating in the high-tech biotechnology market, Vironova's business model revolves around selling specialized TEM equipment, proprietary software, and offering expert analytical services. The company generates revenue through the sale of its products, as well as through service contracts and consulting fees.

Keywords: TEM, nanoparticles, biotechnology, pharmaceutical, software, hardware, analysis, quality control, consulting, high-tech.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.